Home / Archive / Vol. 37 No. 4 (2025): 37-4 / ORIGINAL
A Comparative Analysis of the Therapeutic Efficacy of Budesonide/Glycopyrronium/Formoterol Fumarate versus Budesonide and Tiotropium Dihydrate in Managing COPD Exacerbations, Lung Function, Symptoms, and Quality of Life: A Multicenter Study
Dr Aqsa Sadaf
Postgraduate resident (Internal medicine MU-3) Faisalabad Medical University, Faisalabad
Dr.Ghulam Abbas Tahir
Assistant professor medicine , Faisalabad medical university, Faisalabad.
Dr .Yasir Yaqoob
Assistant professor medicine , Faisalabad medical university, Faisalabad
Dr.Ahmad Zeeshan
Assistant professor medicine , Faisalabad medical university, Faisalabad.
Dr.Irfan Haider
Senior Registrar medicine,allied hospital Faisalabad
Dr Asma Qibtia
Postgraduate Resident (Internal Medicine MU-3) Faisalabad Medical University, Faisalabad
Keywords:
COPD, Budesonide/Glycopyrronium/Formoterol Fumarate, Budesonide and Tiotropium Dihydrate, Multicenter Study, Therapeutic Efficacy, Lung Function, Symptoms, Quality of Life.
Abstract
Background: Chronic Obstructive Pulmonary Disease (COPD) poses a substantial global health burden, necessitating effective therapeutic interventions. This study undertakes a comparative analysis of the therapeutic efficacy of
Budesonide/Glycopyrronium/Formoterol Fumarate (BGF) against Budesonide and Tiotropium Dihydrate (BUD/TIO) in addressing COPD exacerbations, lung function, symptoms, and overall quality of life.
Aim: The primary aim of this multicenter research was to systematically associate medical outcomes and benefits of BGF and BUD/TIO in the management of COPD exacerbations. The study sought to assess their impact on lung function, signs, and overall quality of life experienced by individuals having COPD.
Methods: A multicenter, randomized, double-blind, parallel-group design was employed, involving COPD patients recruited from diverse demographic backgrounds. Applicants were randomly allocated to either BGF or BUD/TIO group, and treatment efficacy was evaluated over a specified duration. Lung function assessments, symptom monitoring, and quality of life measurements were conducted using standardized protocols.
Results: The analysis revealed notable differences in therapeutic efficacy between BGF and BUD/TIO. BGF demonstrated superior outcomes in managing COPD exacerbations, significantly improving lung function parameters, alleviating symptoms, and enhancing the overall quality of life compared to the BUD/TIO group. The results indicated a more comprehensive and effective approach to COPD management with the use of BGF.
Conclusion: This multicenter study provides compelling evidence supporting the enhanced therapeutic efficacy of Budesonide/Glycopyrronium/Formoterol Fumarate over Budesonide and Tiotropium Dihydrate in managing COPD exacerbations. The observed developments in lung function, symptom relief, and overall quality of life underscore potential of BGF as a more effective therapeutic option for individuals with COPD.
References
1. Nigro SC, Sobieraj DM. Budesonide/Glycopyrrolate/Formoterol Fumarate Co-suspension Metered Dose Inhaler: A Triple Therapy for the Treatment of Chronic Obstructive Pulmonary Disease. Annals of Pharmacotherapy. 2022 May;56(5):582-91.
2. Calzetta L, Matera MG, Rogliani P, Cazzola M. The role of triple therapy in the management of COPD. Expert Review of Clinical Pharmacology. 2020 Aug 2;13(8):865-74.
3. Ismaila AS, Haeussler K, Czira A, Youn JH, Malmenäs M, Risebrough NA, Agarwal J, Nassim M, Sharma R, Compton C, Vogelmeier CF. Fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) triple therapy compared with other therapies for the treatment of COPD: a network meta-analysis. Advances in Therapy. 2022 Sep;39(9):3957-78.
4. Sun Y, Molins E, Daoud SZ, Trivedi R, Stewart C, Lamarca R, Bharali P, Garcia-Gil E. Efficacy and safety of aclidinium/formoterol versus monotherapies and aclidinium versus placebo in Chinese and other Asian patients with moderate-to-severe COPD: The AVANT Phase 3 study. Respiratory Medicine. 2023 Nov 1;218:107393.
5. Li A, Chan HP, Gan PX, Liew MF, Wong WF, Lim HF. Eosinophilic endotype of chronic obstructive pulmonary disease: similarities and differences from asthma. The Korean Journal of Internal Medicine. 2021 Nov;36(6):1305
.6. Rogliani P, Ritondo BL, Puxeddu E, Cazzola M, Calzetta L. Impact of long-acting muscarinic antagonists on small airways in asthma and COPD: a systematic review. Respiratory Medicine. 2021 Nov 1;189:106639.
7. Rhodes K, Jenkins M, de Nigris E, Aurivillius M, Ouwens M. Relationship between risk, cumulative burden of exacerbations and mortality in patients with COPD: modelling analysis using data from the ETHOS study. BMC Medical Research Methodology. 2022 May 25;22(1):150.
8. Pelaia C, Procopio G, Rotundo FL, Deodato MR, Ferrante Bannera A, Tropea FG, Cancelliere A, Vatrella A, Pelaia G. Real-life therapeutic effects of beclomethasone dipropionate/formoterol fumarate/glycopyrronium combined triple therapy in patients with chronic obstructive pulmonary disease. Therapeutic Advances in Respiratory Disease. 2023 Feb;17:17534666231155778.
9. Strange C, Tkacz J, Schinkel J, Lewing B, Agatep B, Swisher S, Patel S, Edwards D, Touchette DR, Portillo E, Feigler N. Exacerbations and Real-World Outcomes After Single-Inhaler Triple Therapy of Budesonide/Glycopyrrolate/Formoterol Fumarate, Among Patients with COPD: Results from the EROS (US) Study. International Journal of Chronic Obstructive Pulmonary Disease. 2023 Dec 31:2245-56.
10. Hu F, Lv F. Effect of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler combined with nasal high-flow nasal cannula on elderly patients with COPD and respiratory failure. Pakistan Journal of Medical Sciences. 2024 Jan;40(3Part-II):353.
11. Deslee G, Poccardi N, Fabry-Vendrand C, Leynaud D, Thabut G, Eteve-Pitsaer C, Coriat A, Ghout I, Leleu H. First Real-World Evidence on budesonide/glycopyrronium/formoterol fumarate (BGF) use for COPD patients in France (ENARXI study): an interim analysis.
12. Marshall J, Sharma A, Darken P, Ouwens M, Singh B, Tansey-Dwyer D. Letter to the Editor Regarding “Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-Analysis”. Advances in Therapy. 2023 May;40(5):2549-55.
13. Ohtsuka K, Harada N, Horiuchi A, Umemoto S, Kurabatashi R, Yui A, Yamamura H, Shinka Y, Miyao N. Therapeutic Response to Single-Inhaler Triple Therapies in Moderate-to-Severe COPD. Respiratory Care. 2023 Mar 1;68(3):330-7.
14. Sun Y, Molins E, Daoud SZ, Trivedi R, Stewart C, Lamarca R, Bharali P, Garcia-Gil E. Efficacy and safety of aclidinium/formoterol versus monotherapies and aclidinium versus placebo in Chinese and other Asian patients with moderate-to-severe COPD: The AVANT Phase 3 study. Respiratory Medicine. 2023 Nov 1;218:107393.
15. Jackson D, Jenkins M, de Nigris E, Purkayastha D, Patel M, Ouwens M. Associations between the EQ-5D-5L and exacerbations of chronic obstructive pulmonary disease in the ETHOS trial. Quality of Life Research. 2024 Jan 11:1-1.
16. Suissa S. Triple therapy in COPD: understanding the data. ERJ Open Research. 2023 Jan 1;9(1).
17. Ismaila AS, Haeussler K, Malmenäs M, Sharma R, Compton C, Vogelmeier CF, Han MK, Halpin DM. A Response to: Letter to the Editor Regarding “Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-analysis”. Advances in Therapy. 2023 May;40(5):2556-61.
18. Naseem S, Nadella S, Reddy AR, Poornima KN. TRIPLE THERAPY IN COPD: A GAME-CHANGER?-EXAMINING ETHOS, IMPACT &TRIBUTE STUDIES. EPRA International Journal of Multidisciplinary Research (IJMR). 2023 Jul 8;9(7):30-2.
19. Xi Q, Miao J, Cao Z, Wang H. Inhalable aerosol microparticles with low carrier dosage and high fine particle fraction prepared by spray-freeze-drying. International Journal of Pharmaceutics: X. 2023 Dec 1;5:100158.
20. Gonzales J, Fraidenburg DR. Pharmacology and Emerging Therapies for Group 3 Pulmonary Hypertension Due to Chronic Lung Disease. Pharmaceuticals. 2023 Mar 9;16(3):418.
21. Gresse E, Rousseau J, Akdim M, Du Bois A, Lechanteur A, Evrard B. Enhancement of inhaled micronized powder flow properties for accurate capsules filling. Powder Technology. 2024 Feb 27:119576.
22. Wang J, Wang P, Shao Y, He D. Advancing Treatment Strategies: A Comprehensive Review of Drug Delivery Innovations for Chronic Inflammatory Respiratory Diseases. Pharmaceutics. 2023 Aug 17;15(8):2151.
23. Kadrichu N. Advances and future trends in medical inhalers. InAdvances in Drug Delivery Systems for Healthcare: From concept to clinic 2024 Jan 1 (pp. 7-1). Bristol, UK: IOP Publishing.
24. Cazzola M, Page CP, Wedzicha JA, Celli BR, Anzueto A, Matera MG. Use of thiols and implications for the use of inhaled corticosteroids in the presence of oxidative stress in COPD. Respiratory research. 2023 Jul 31;24(1):194.
25. Akita T, Morita Y, Kawai T, Oda K, Tange K, Nakai Y, Yamashita C. Am80-Encapsulated Lipid Nanoparticles, Developed with the Aim of Achieving Alveolar Regeneration, Have an Improvement Effect on Pulmonary Emphysema. Pharmaceutics. 2023 Jan;15(1):37.
Published
2026-07-20
License
Copyright (c) 2026 Fatima Iqbal, Myeda Butool, Maliha Khalid Khan, Firza Fatima, Bisma Zafar, Muhammad Hassan, Mushayyad Hussain.
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
Journal of Ayub Medical College, Abbottabad is an OPEN ACCESS JOURNAL which means that all content is FREELY available without charge to all users whether registered with the journal or not. The work published by J Ayub Med Coll Abbottabad is licensed and distributed under the creative commons License CC BY ND Attribution-NoDerivs. Material printed in this journal is OPEN to access, and are FREE for use in academic and research work with proper citation. J Ayub Med Coll Abbottabad accepts only original material for publication with the understanding that except for abstracts, no part of the data has been published or will be submitted for publication elsewhere before appearing in J Ayub Med Coll Abbottabad. The Editorial Board of J Ayub Med Coll Abbottabad makes every effort to ensure the accuracy and authenticity of material printed in J Ayub Med Coll Abbottabad. However, conclusions and statements expressed are views of the authors and do not reflect the opinion/policy of J Ayub Med Coll Abbottabad or the Editorial Board.
USERS are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author. This is in accordance with the BOAI definition of open access.
AUTHORS retain the rights of free downloading/unlimited e-print of full text and sharing/disseminating the article without any restriction, by any means including twitter, scholarly collaboration networks such as ResearchGate, Academia.edu, and social media sites such as Twitter, LinkedIn, Google Scholar and any other professional or academic networking site.
P-ISSN: 1025-9589
E-ISSN: 1819-2718
